BrightSpring Health Services, Inc. Common Stock (BTSG) Stock Analysis
Latest ClaritX AI analysis ·
BrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance. Patients receive care from a dedicated team of clinical professionals and licensed pharmacists. Formerly known as Phoenix Parent Holdings Inc., the company officially adopted the name BrightSpring Health Services, Inc. in May 2021. Founded in 1974, its headquarters are located in Louisville, Kentucky.
| Metric | Value |
|---|---|
| Price | $60.25 |
| Market cap | $11.8B |
| Sector | Healthcare |
| Industry | Medical - Healthcare Information Services |
| ClaritX AI score | 52/100 |
| Price/Book | 6.06 |
| Beta | 1.85 |
AI verdict
BrightSpring Health Services, Inc. (BTSG) currently presents a highly complex, aggressive investment profile defined by a severe divergence between euphoric Wall Street growth projections and heavily constrained fundamental realities. Currently trading at $60.25, the asset remains trapped roughly 18.3% below its established 52-week high of $73.75. For a stock to suffer an 18.3% drawdown during a period of relentless analyst "Buy" recommendations explicitly indicates that the staggering liquidation of over 72.3 million insider shares earlier in 2026 continues to act as a massive structural ceiling, aggressively suffocating organic upward price discovery. A stock languishing at these depths on purportedly flawless news represents a far more treacherous risk proposition than one trading near all-time highs with organic market conviction. Coupled with an exceptionally elevated beta of 1.85, BTSG guarantees violent volatility, firmly categorizing the asset as a high-risk momentum vehicle rather than a stable healthcare holding. While the stock has recently demonstrated constructive technical momentum by reclaiming its 20-day moving average, the underlying enterprise remains fundamentally bound by a highly leveraged balance sheet carrying a 1.165 Debt-to-Equity ratio alongside razor-thin 2.05% net profit margins. Wall Street optimistically projects a lofty $79.14 price target anchored in M&A expansion and AI-driven efficiencies, yet the impending $200 million IRA regulatory revenu
What this score has been worth
ClaritX scores BTSG 52 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 208 analyses that scored in the 50-69 band, the average forward return was -5.5% with a 40% win rate, -10.3pp against the S&P 500. That is a measured tendency across many names, not a forecast for BTSG — roughly 60% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.